Physician profile
Eric Jacobson
NPI 1497762397
$7,497.41
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,840 · 2020: $1,700 · 2021: $2,030 · 2022: $1,752 · 2023: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $175.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $1,466.82 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $1,211.84 | 2019-2022 | |
| Abbvie INC. | $907.06 | 2021-2023 | |
| Allergan, INC. | $822.11 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $429.22 | 2020-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $383.15 | 2019-2022 | |
| Alkermes, INC. | $375.27 | 2019-2023 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $344.45 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $250.73 | 2019-2021 | |
| Lundbeck LLC | $243.34 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $148.87 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $135.36 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $130.24 | 2019-2023 | Austedo |
| Eisai INC. | $119.91 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $113.71 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $94.24 | 2019-2020 | |
| Shire North American Group INC | $48.90 | 2019 | |
| Jazz Pharmaceuticals INC. | $45.06 | 2019-2021 | |
| Axsome Therapeutics, INC. | $40.06 | 2022 | |
| Boston Scientific Corporation | $39.24 | 2021-2022 | |
| Corium, LLC | $26.78 | 2022 | |
| Alfasigma USA, INC. | $26.04 | 2020 | |
| Bausch Health US, LLC | $19.51 | 2019 | |
| Idorsia Pharmaceuticals US INC | $18.45 | 2022 | |
| Neuronetics, INC. | $16.37 | 2020 | |
| Ironshore Pharmaceuticals INC. | $16.07 | 2020 | |
| Neos Therapeutics, Lp | $13.16 | 2019 | |
| Adlon Therapeutics L.P. | $11.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Jacobson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.